Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Q1 2022 Blueprint Medicines Corp Earnings Call Transcript

May 03, 2022 / 12:30PM GMT
Release Date Price: $62.82 (+5.19%)
Operator

Morning. My name is Juan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines First Quarter 2022 Financial Results Conference Call. (Operator Instructions) Thank you.

I would now like to turn the call over to your host, Jenna Cohen from Blueprint Medicines. Jenna, you may begin your conference.

Jenna Cohen
Blueprint Medicines Corporation - Senior Director & Head of IR

Thank you, Juan. Good morning, everyone, and welcome to Blueprint Medicine's First Quarter 2022 Financial and Operating Results Conference Call. This morning, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today, by going to the Investor set of our website at www.blueprintmedicines.com.

Today on our call Kate Haviland, our Chief Executive Officer, will discuss Blueprint Medicine's pillars for growth through 2023. Christy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot